The Moderna COVID-19 vaccine produces neutralizing antibody titers against the Delta variant, although fewer than against the ancestral strain of the virus, the company announced yesterday.

Based on serum samples collected from eight phase 1 trial participants one week after the second dose of the vaccine, the reduction in neutralizing titers ranged from 2.1-fold for the Delta variant to 8.4-fold for Beta variants of the virus, although all the variants tested remained susceptible to mRNA-1273-elicited serum neutralization, the company said.

“These new data are encouraging and reinforce our belief that the Moderna COVID-19 Vaccine should remain protective against newly detected variants,” said CEO Stéphane Bancel.

 

Related News Articles

Headline
Commenting on a forthcoming Centers for Medicare & Medicaid Services’ rule requiring COVID-19 vaccinations for workers in most health care settings…
Chairperson's File
On this episode, I discuss emergency preparedness, caregiver resiliency and health equity — all through the lens of the COVID-19 pandemic — with Fritz Francois…
Headline
The Centers for Medicare & Medicaid Services today announced that the agency will pay for Medicare beneficiaries’ booster doses, without cost sharing…
Headline
AHA today urged the Office of the United States Trade Representative to extend the current Section 301 tariff exemptions for certain medical devices to ensure…
Headline
The Centers for Disease Control and Prevention early Friday morning opted for a broad endorsement of Pfizer COVID-19 vaccine booster shots, issuing interim…
Headline
The AHA today urged the Health Resources and Services Administration to quickly distribute the $17 billion in Phase 4 provider relief funds and $8.5 billion in…